HER-2 Protein Overexpression

20 clinical trials · Condition

Record	Firm	Date
Trastuzumab and Standard Treatment With Chemo- and Immunotherapy as First Line Treatment for HER2 Positive Esophageal Squamous Cell Carcinoma Patients (NCT05170256)	Morten Mau-Sørensen	2022-02-04
HER2 Chimeric Antigen Receptor (CAR) T Cells in Combination With Checkpoint Blockade in Patients With Advanced Sarcoma (NCT04995003)	Baylor College of Medicine	2021-12-07
ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer (NCT04602117)	QuantumLeap Healthcare Collaborative	2021-07-28
Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers (NCT04464967)	NKGen Biotech, Inc.	2021-03-01
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors (NCT04660929)	Carisma Therapeutics Inc	2021-02-02
Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors (NCT04650451)	Bellicum Pharmaceuticals	2020-12-07
Testing a New Imaging Agent to Identify Cancer (NCT04692831)	Memorial Sloan Kettering Cancer Center	2020-11-30
Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor (NCT04215159)	Jin-Hee Ahn	2019-12-30
The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor (NCT04179656)	Tianjin Medical University Second Hospital	2019-12-01
Trastuzumab in HER2-positive Biliary Tract Cancer (NCT03613168)	Changhoon Yoo	2019-06-01
Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1 (NCT03630809)	H. Lee Moffitt Cancer Center and Research Institute	2019-01-10
Long-Term Follow-Up Study of Subjects Treated With ACTR T Cell Product (NCT02840110)	Cogent Biosciences, Inc.	2016-10-01

Track HER-2 Protein Overexpression automatically

Every clearance here is in the API, with alerts when new ones post.